# IMCODE 003 (NCT05968326)

> A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05968326
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Genentech, Inc.
- Conditions: Adenocarcinoma, Pancreatic Ductal
- Interventions: Autogene cevumeran; Atezolizumab; mFOLFIRINOX
- Enrollment: 260
- Primary outcome: Disease Free Survival (DFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=imcode-003-nct05968326